Coventry University
Coventry, West Midlands, CV1 5FB, United Kingdom
NCT Number: NCT03299972
The aim of this randomised, double-blind, placebo-controlled, parallel groups trial is to investigate the effects of 12 weeks resistance exercise and whey protein supplementation on energy metabolism, markers of appetite, inflammation and hormonal response and body composition and strength and functional performance.
Generally healthy, retired men aged 60-80 years will be recruited (n = 52 in total, n = 13 per group). Participants will be randomised to either: a) control group, b) whey protein supplement group, c) resistance exercise + control group or d) resistance exercise + whey protein supplementation group.
Looking for future studies?
Notify Me60 year–80 year
Male
Interventional
Not applicable
Coventry, West Midlands, CV1 5FB, United Kingdom
With demographics indicating that the world's population aged >60 years will increase from 600 million reported in 2000, to >2 billion by 2050, there is an increasing interest in health issues related to ageing. One area of particular interest is sarcopenia, defined as the progressive loss of muscle mass, strength and physical function as a consequence of ageing. Sarcopenia has been associated with an increase in cardiovascular disease, poor metabolic and cognitive function, reduced quality of life and early mortality. Studies have reported beneficial effects of both resistance exercise and increasing protein intake independently and in combination on markers of sarcopenia (mostly increases in muscle mass, strength and physical function). However, little is known about the effects of combined intervention on energy metabolism, appetite and cognitive and endocrine function. This randomised, double-blind, placebo-controlled, parallel groups trial will investigate these, alongside assessing the effects of combined intervention on total lean tissue mass, muscular strength and functional performance.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
25 g whey protein supplementation twice daily (breakfast and lunch)
23.75 g maltodextrin twice daily (breakfast and lunch)
60 minutes of resistance exercise twice a week
Time frame: 0 to 12 weeks
Measured by whole-room calorimetry
Time frame: 0 to 12 weeks
Fat-free mass, fat mass, skeletal muscle mass measured by bio-electrical impedance analysis
Time frame: 0 to 12 weeks
Measured by whole-room calorimetry
Time frame: 0 to 12 weeks
Ghrelin, leptin, and PYY
Time frame: 0 to 12 weeks
Time frame: 0 to 12 weeks
Time frame: 0 to 12 weeks
Tumor necrosis factor alpha (TNF-α), C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-10 (IL-10), Annexin A1
Time frame: 0 to 12 weeks
24 Hour Continuous Glucose Monitoring
Time frame: 0 to 12 weeks
Time frame: 0 to 12 weeks
Time frame: 0 to 12 weeks
Balance, Gait speed and time to sit and stand from a chair 5 times
Time frame: 0 to 12 weeks
Time frame: 0 to 12 weeks
Time frame: 0 to 12 weeks
Time frame: 0 to 12 weeks
Accelerometer
Time frame: 0 to 12 weeks
Coventry University
Other
Effects of 12 Weeks Resistance Exercise and Whey Protein Supplementation on Energy Metabolism, Appetite, Body Composition and Biomarkers Related to Sarcopenia and Metabolic Health
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06910254
Atrophy, Brain Diseases
Seoul, South Korea
View Trial DetailsNCT06556706
Aging, Atrophy
Montreal, Canada
View Trial DetailsNCT04772040
Aging, Atrophy
Stirling, Stirlingshire, United Kingdom
View Trial DetailsNCT02467153
Atrophy, Behavior
Birmingham, United Kingdom
View Trial Details